Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct 14:S0741-5214(25)01842-7.
doi: 10.1016/j.jvs.2025.10.008. Online ahead of print.

Noncontrast magnetic resonance angiography outperforms digital subtraction angiography in detecting hibernating below-the-knee arteries and downgrades Transatlantic Inter-Society Consensus and Global Limb Anatomic Staging System scores in chronic limb-threatening ischemia patients

Affiliations
Free article

Noncontrast magnetic resonance angiography outperforms digital subtraction angiography in detecting hibernating below-the-knee arteries and downgrades Transatlantic Inter-Society Consensus and Global Limb Anatomic Staging System scores in chronic limb-threatening ischemia patients

Alexander B Crichton et al. J Vasc Surg. .
Free article

Abstract

Objective: Current imaging techniques are limited in their ability to accurately characterize below-the-knee diseased vessels. Digital subtraction angiography (DSA) remains the gold standard but may not visualize some vessels because it relies on nephrotoxic contrast that can fail to reach and opacify distal vessels. Quiescent-interval single shot (QISS) magnetic resonance imaging (MRI) images patients without exposure to nephrotoxic agents such as gadolinium or ionizing radiation and has been suggested to show "hibernating vessels" that are not visualized on DSA. The aim of this study is to evaluate whether QISS MRI would identify more patent vessels when compared with DSA, and whether this resulted in less severe Transatlantic Inter-Society Consensus (TASC) II and Global Limb Anatomic Staging System (GLASS) grades.

Methods: Patients with CLTI undergoing QISS MRI and DSA were included. Two examiners reviewed the imaging of each patient on both modalities. The vessels assessed were the popliteal and infrapopliteal arteries. All vessels were split into three sections (eg, anterior tibial artery [ATA]1, proximal; AT2, middle; and AT3, distal) and scored as either patent or occluded as individual segments (except the tibioperoneal and dorsalis pedis arteries, which were counted as one segment each). Following this, TASC II and infrapopliteal GLASS scoring was performed and compared between QISS MRI and DSA.

Results: A total of 41 patients were evaluated. Overall, 570 vessel segments were analyzed, with a significantly higher number of patent vessel segments found on QISS MRI compared with DSA (66% vs 58%; P < .001). On single-vessel analysis, there was a higher level of patency seen on QISS MRI compared with DSA in the peroneal (72% vs 61%; P = .001), posterior tibial (54% vs 42%; P = .001), anterior tibial (60% vs 52%; P = .01), and dorsalis pedis arteries (65% vs 38%). Overall TASC II and GLASS scoring did not significantly differ when comparing DSA and QISS MRI. Subgroup analysis of TASC D and infrapopliteal GLASS 4 lesions showed that vessels were significantly more likely to be downgraded to lower grade lesions when interpreting images using QISS MRI in comparison to DSA.

Conclusions: QISS MRI can identify more patent vessel segments when compared with the current gold standard, DSA. This study also suggests that QISS MRI may result in lower grading on TASC II and GLASS scoring of the most severe spectrum of arterial disease. The improved visualization with QISS may expand the range of viable treatment options for patients with complex below-the-knee disease in chronic limb-threatening ischemia.

Keywords: CLTI; Hibernating vessels; Noncontrast MRI; Peripheral artery disease; QISS MRI.

PubMed Disclaimer

Conflict of interest statement

Disclosures T.R. reports research funding from Light Matter Interaction, Inc, Baylis Medical Technologies, and BSCI; and ownership: co-founder and director of Magellan Biomedical Inc. The remaining authors report no conflicts.

LinkOut - more resources